Digest Network Come funziona
Network
/
Società
Th
Non verificato

Thetis Pharmaceuticals LLC

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati
05/05/2025
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Thetis Pharmaceuticals Presents New Preclinical and Clinical Data forTP-317 at DDW 2025
Fonte
Thetis Pharmaceuticals LLC
Emittente
Business Wire
1.00
0
19/02/2025
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at ECCO 2025
Fonte
Thetis Pharmaceuticals LLC
Emittente
Business Wire
1.00
0
09/01/2025
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Thetis Pharmaceuticals Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance TP-317, an Oral BLT1 Agonist, into a Phase 1b Trial in Ulcerative Colitis Patients
Fonte
Thetis Pharmaceuticals LLC
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0